Laboratory Products 27 Revolutionising neuromuscular disease research through 3D modelling
A recent case study published by AMSBIO highlights ground-breaking research in neuromuscular diseases. Led by Dr Roger Kamm at the Massachusetts Institute of Technology (MIT), this project focuses on developing a 3D microfl uidic neuromuscular platform for modelling Motor Neuron Diseases (MNDs).
MNDs, particularly amyotrophic lateral sclerosis (ALS), remain a signifi cant medical challenge with a limited life expectancy of 2 to 5 years. The complexity of these diseases and a lack of in-depth understanding have hindered effective treatments.
MIT researchers have made notable progress using CELLBANKER® 1 and STEM-CELLBANKER® cryopreservation media from AMSBIO. These advancements have the potential to transform drug discovery and enhance our comprehension of MND development.
Dr Kamm emphasised that previous MND drug discovery methods often overlooked the role of skeletal muscle cells. The newly developed 3D neuromuscular model presents a broader perspective on pathology and offers a novel path to identify treatments that target both motor neurons and muscle cells, addressing the complex nature of MNDs.
The research protocol features a microfl uidic chip with separate compartments for each cell type, closely mimicking living tissue. Induced pluripotent stem cells (iPSCs) from healthy donors or ALS patients were differentiated into neural stem cells, then expanded and cryogenically preserved using STEM-CELLBANKER®
from AMSBIO.
This innovative approach holds great promise to tailor treatments to individual genetics and drug responses, enhancing effectiveness while minimising side effects. By providing a more accurate disease representation, the 3D neuromuscular model may accelerate drug discovery and streamline the transition from laboratory research to clinical applications.
For the full case study, please visit
ilmt.co/PL/ymnQ AMSBIO’s CELLBANKER®
More information online:
ilmt.co/PL/0QeJ series of cell freezing media enables the stable long-term storage of cells. Its unique formulation ensures stable cryopreservation and high viability after freeze-thaw
procedures, making it a trusted solution for storing any cell type, including sensitive cell lines. This series offers various formulations, providing high cell viability (>90%) in serum, serum-free, GMP, and DMSO-free formats.
61489pr@reply-direct.com
Advancing photochemistry with expanded wavelength options
Asynt is pleased to announce the expansion of its LightSyn Lighthouse photochemistry platform with a wide array of additional wavelength modules. Responding to customer demand, Asynt now offers 11 different wavelength options
for researchers engaged in photochemical reactions with the LightSyn Lighthouse.
In addition to the original 460 nm and 365 nm options introduced earlier this year, users can now select from lamp modules with wavelengths of 390 nm, 395 nm, 410 nm, 523 nm, 590 nm, 623 nm, 740 nm, 850 nm, 940 nm, and cool white LEDs.
The LightSyn Lighthouse uniquely directs light produced by these modules through a quartz light pipe directly into the sample, minimising the distance light travels from the LED to nearly zero. This design enhances the exposure power to the medium and signifi cantly improves photon fl ux effi ciency, all without adding extra heat generated from the electronics.
Featuring built-in safety measures to minimise exposure risks, including a microswitch preventing light emission when the device is not sealed, the LightSyn Lighthouse by Asynt ensures user-friendly operation. Asynt also provides a heating/cooling base for the device, allowing precise temperature control from -30ºC to 80ºC when used with an appropriate circulator.
With a single power supply and standard fi ttings, users can safely set up and conduct photochemical reactions with ease, achieving repeatable results. Asynt’s commitment to providing laboratory tools ‘By chemists, for chemists’ is evident in the LightSyn Lighthouse’s design, allowing straightforward customisation for various applications, including gas reactions/bubbling, programmed reaction management, sample addition or removal, and potential use in fl ow chemistry setups with multiple LightSyn Lighthouse units.
More information online:
ilmt.co/PL/WlpZ 61713pr@reply-direct.com
Compliance software and validation services for precision particle sizing
Testa Analytical has launched a new 21CFR Part 11 compliance software designed for its NanoBrook particle sizing and zeta potential instrumentation. Particle size and zeta potential determination are crucial quality control measures, especially in regulated sectors such as the pharmaceutical industry. The compliance software ensures adherence to 21CFR Part 11 guidelines, offering password-protected roles for lab personnel, activity logging, and data integrity maintenance to prevent manipulation.
This user-friendly software provides detailed documentation of processes, methods, operator activities, and instrument validation, making it a valuable tool for labs prioritising result reliability. However, compliance software alone isn’t enough to meet regulations; regular performance validation is essential. Testa Analytical Solutions offers a comprehensive portfolio of validation services, including IQ/OQ/PQ (and, if required, MQ), ensuring NanoBrook instruments comply with 21 CFR 11 regulations.
More information online:
ilmt.co/PL/6KBX 61732pr@reply-direct.com
Laboratory and Research Grade Autoclaves
Call: +44 (0)20 8316 6620 Email:
sales@priorclave.co.uk
More than 70 energy efficient models all with proven reliability. Plus our extended ranges BASE - SMART - PERFORMANCE ensure you can match more easily our standard autoclaves to your sterilising requirements.
www.priorclave.com
WWW.LABMATE-ONLINE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
